Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Maravai LifeSciences Holdings Inc’s stock clocked out at $5.23, up 9.64% from its previous closing price of $4.77. In other words, the price has increased by $9.64 from its previous closing price. On the day, 1.94 million shares were traded. MRVI stock price reached its highest trading level at $5.25 during the session, while it also had its lowest trading level at $4.64.
Ratios:
To gain a deeper understanding of MRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.94 and its Current Ratio is at 10.74. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.59.
On December 05, 2024, Goldman Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $4.25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when DeFord John A bought 17,500 shares for $5.75 per share. The transaction valued at 100,625 led to the insider holds 70,046 shares of the business.
HULL CARL bought 175,000 shares of MRVI for $987,000 on Nov 11 ’24. The insider now owns 175,000 shares after completing the transaction at $5.64 per share. On May 28 ’24, another insider, GTCR INVESTMENT XI LLC, who serves as the Director of the company, sold 9,940,974 shares for $9.81 each. As a result, the insider received 97,570,660 and left with 20,150,005 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 1320721408 and an Enterprise Value of 1045014528. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.77 while its Price-to-Book (P/B) ratio in mrq is 2.15. Its current Enterprise Value per Revenue stands at 3.774 whereas that against EBITDA is 1008.701.
Stock Price History:
The Beta on a monthly basis for MRVI is -0.08, which has changed by -0.2205882 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $11.56, while it has fallen to a 52-week low of $4.28. The 50-Day Moving Average of the stock is -4.06%, while the 200-Day Moving Average is calculated to be -32.34%.
Shares Statistics:
It appears that MRVI traded 1.99M shares on average per day over the past three months and 2277930 shares per day over the past ten days. A total of 141.59M shares are outstanding, with a floating share count of 117.45M. Insiders hold about 17.20% of the company’s shares, while institutions hold 89.83% stake in the company. Shares short for MRVI as of 1735603200 were 8507989 with a Short Ratio of 4.28, compared to 1732838400 on 7904243. Therefore, it implies a Short% of Shares Outstanding of 8507989 and a Short% of Float of 7.1499999999999995.
Earnings Estimates
The current market rating for Maravai LifeSciences Holdings Inc (MRVI) reflects the collective analysis of 14.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.0 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.06 and -$0.1 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.06, with 14.0 analysts recommending between $0.01 and -$0.2.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $57.84M. It ranges from a high estimate of $60.4M to a low estimate of $56.7M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $74.14MFor the next quarter, 11 analysts are estimating revenue of $63.62M. There is a high estimate of $72.1M for the next quarter, whereas the lowest estimate is $52M.
A total of 12 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $263.2M, while the lowest revenue estimate was $259.5M, resulting in an average revenue estimate of $260.57M. In the same quarter a year ago, actual revenue was $288.94MBased on 16 analysts’ estimates, the company’s revenue will be $266.58M in the next fiscal year. The high estimate is $296.63M and the low estimate is $234.41M.
